FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 311:878-882 October 4, 1984 Number 14 Next

	Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

Abstract

Certain patients receiving hemodialysis experience recurrent chest pain, dyspnea, and hypotension during exposure to new cuprophane-membrane dialyzers (the "first-use syndrome"). Because activation of complement may be involved in these events, we examined in vivo complement activation with new cuprophane membranes and in vitro activation by zymosan in 6 such patients, and compared them with 10 patients who did not have symptoms during dialysis. All patients with the first-use syndrome had maximal complement activation 10 minutes after initiation of dialysis, with C3a des-arginine (desArg), the stable metabolite of C3 activation, equal to 8533 +/- 157 ng per milliliter (mean +/- S.E.M.). In asymptomatic patients the maximal C3a desArg value occurred at 15 minutes and was only 2907 +/- 372 ng per milliliter (P less than or equal to 0.0001). At a concentration of 3.8 x 10(-5) g of zymosan per milliliter, patients with the first-use syndrome had a C3a desArg level of 29.6 +/- 1.4 micrograms per milliliter, whereas it was only 16.6 +/- 2.3 micrograms per milliliter in asymptomatic patients (P less than or equal to 0.0001). Two other patients, who experienced cardiopulmonary collapse during the first two minutes of dialysis, had a C3a desArg level of 18,900 and 7800 ng per milliliter, respectively. We conclude that the occurrence of adverse symptoms associated with new cuprophane-membrane dialyzers correlates with complement activation.

This article has been cited by other articles:

• Gill, N., Nally, J. V. Jr, Fatica, R. A. (2005). Renal Failure Secondary to Acute Tubular Necrosis: Epidemiology, Diagnosis, and Management. Chest 128: 2847-2863 [Abstract] [Full Text]  
• Koller, H., Hochegger, K., Zlabinger, G. J., Lhotta, K., Mayer, G., Rosenkranz, A. R. (2004). Apoptosis of human polymorphonuclear neutrophils accelerated by dialysis membranes via the activation of the complement system. Nephrol Dial Transplant 19: 3104-3111 [Abstract] [Full Text]  
• Mitch, W. E (2003). Getting beyond cross-sectional studies of abnormal nutritional indexes in dialysis patients. Am. J. Clin. Nutr. 77: 760-761 [Full Text]  
• Coppo, R., Amore, A. (2000). Importance of the bradykinin-nitric oxide synthase system in the hypersensitivity reactions of chronic haemodialysis patients. Nephrol Dial Transplant 15: 1288-1290 [Full Text]  
• MOIST, L. M., PORT, F. K., ORZOL, S. M., YOUNG, E. W., OSTBYE, T., WOLFE, R. A., HULBERT-SHEARON, T., JONES, C. A., BLOEMBERGEN, W. E. (2000). Predictors of Loss of Residual Renal Function among New Dialysis Patients. J. Am. Soc. Nephrol. 11: 556-564 [Abstract] [Full Text]  
• ROSENKRANZ, A. R., KÖRMÖCZI, G. F., THALHAMMER, F., MENZEL, E. J., HÖRL, W. H., MAYER, G., ZLABINGER, G. J. (1999). Novel C5-Dependent Mechanism of Neutrophil Stimulation by Bioincompatible Dialyzer Membranes. J. Am. Soc. Nephrol. 10: 128-135 [Abstract] [Full Text]  
• Pastan, S., Bailey, J. (1998). Dialysis Therapy. NEJM 338: 1428-1437 [Full Text]  
• Thadhani, R., Pascual, M., Bonventre, J. V. (1996). Acute Renal Failure. NEJM 334: 1448-1460 [Full Text]  
• Jayabalan, M. (1995). Sterilization and Reprocessing of Materials and Medical Devices--Reusability. J Biomater Appl 10: 97-112 [Abstract]  
• Moen, O., Fosse, E., Braten, J., Andersson, C., Fagerhol, M. K., Venge, P., Hegasen, K., Mollnes, T. E. (1994). Roller and centrifugal pumps compared in vitro with regard to haemolysis, granulocyte and complement activation. Perfusion 9: 109-117 [Abstract]  
• Mickleborough, L. L, Arnold, G., Chiu, R. C-J (1986). Complement consumption during cardiopulmonary bypass: bubble versus membrane oxygenators. Perfusion 1: 261-269 [Abstract]